GEN Exclusives

More »

GEN News Highlights

More »
Mar 10, 2009

Avexa and Progen Nix Merger Deal

  • Avexa and Progen Pharmaceuticals have agreed to terminate their merger plans. The companies realized that Progen shareholders would not approve the transaction. Consistent with the terms of the MIA, Progen will pay Avexa a break fee of A$500,000.

    Avexa made a move to take over Progen in December 2008. The combined company would focus initially on Avexa’s Phase III HIV therapy, ATC, and continue to develop selected compounds for infectious diseases and cancer.

    Then at the beginning of this year, Cytopia raised issues with the merger, claiming the combination would not have sufficient money to fund the Phase III trials in HIV. In February, Avexa reaffirmed its interest and reiterated that financing would not be an issue.

    While Avexa expected to have $60 million in cash through the merger with Progen, which would support ATC, the company says that it is still confident about its development efforts. The company anticipates initial Phase III results in the 2nd quarter of 2009.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Patient Access to Genetic Information

Do you think patients have the absolute right to gain access to their own genetic information from medical or clinical laboratories?

More »